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Toxicogenomics is a new scientiﬁc ﬁeld in
which researchers study how the genome
responds to environmental stressors or toxi-
cants (Aardema and MacGregor 2002;
Afshari 2002; Burchiel et al. 2001; Fielden
and Zacharewski 2001; Hamadeh et al.
2002a; Nuwaysir et al. 1999; Olden 2002;
Tennant 2002; Thomas et al. 2001; Ulrich
and Friend 2002). It combines studies of
genetics, genomic-scale mRNA expression
(transcriptomics), cell and tissuewide pro-
tein expression (proteomics), metabolite
profiling (metabonomics), and bioinfor-
matics with conventional toxicology in an
effort to understand the role of gene–
environment interactions in disease. New
molecular technologies such as DNA
microarray analysis and protein chips can
measure the expression of hundreds to
thousands of genes and proteins at a time,
providing the potential to accelerate
discovery of toxicant pathways and speciﬁc
chemical and drug targets. The power and
potential of these new toxicogenomics
methods are capable of revolutionizing
the field of toxicology. In recognition
of this fact, the National Institute of
Environmental Health Sciences (NIEHS)
has created the National Center for
Toxicogenomics (NCT; http://www.niehs.
nih.gov/nct/concept.htm). The NCT has ﬁve
major goals:
1) To facilitate the application of gene and
protein expression technology 
2) To understand the relationship between
environmental exposures and human
disease susceptibility 
3) To identify useful biomarkers of disease
and exposure to toxic substances
4) To improve computational methods for
understanding the biological conse-
quences of exposure and responses to
exposure 
5) To create a public database of environ-
mental effects of toxic substances in
biological systems
The NCT was formally established in
September 2000 and is working to imple-
ment a strategy through which these goals
can be achieved. This article is an initial
response to goal 5. It delineates the concep-
tual framework and some major design
considerations for the proposed Chemical
Effects in Biological Systems (CEBS)
knowledge base. The concept is open for
discussion and debate.
Ideker et al. (2001) have used the
phrase “systems biology” to describe the
integrated study of biological systems at the
molecular level—involving perturbation of
systems, monitoring molecular expression,
integrating response data, and modeling
the system structure and function. Here we
similarly use the phrase “systems toxicol-
ogy” to describe the toxicogenomics evalu-
ation of biological systems, involving
perturbation by toxicants and stressors,
monitoring molecular expression and con-
ventional toxicological parameters, and
iteratively integrating response data. CEBS
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The National Center for Toxicogenomics is developing the ﬁrst public toxicogenomics knowledge
base that combines molecular expression data sets from transcriptomics, proteomics, metabonom-
ics, and conventional toxicology with metabolic, toxicological pathway, and gene regulatory net-
work information relevant to environmental toxicology and human disease. It is called the
Chemical Effects in Biological Systems (CEBS) knowledge base and is designed to meet the infor-
mation needs of “systems toxicology,” involving the study of perturbation by chemicals and stres-
sors, monitoring changes in molecular expression and conventional toxicological parameters, and
iteratively integrating biological response data to describe the functioning organism. Based upon
functional genomics approaches used successfully in analyzing yeast gene expression data sets,
relational and descriptive compendia will be assembled for toxicologically important genes,
groups of genes, single nucleotide polymorphisms (SNPs), and mutant and knockout phenotypes.
CEBS data sets will be fully documented in the experimental protocol and therefore searchable by
compound, structure, toxicity end point, pathology end point, gene, gene group, SNP, pathway,
and network as a function of dose, time, and the phenotype of the target tissue. A knowledge base
is being developed by assimilating toxicological, biological, and chemical information from multi-
ple public domain databases and by progressively reﬁning that information about gene, protein,
and metabolite expression for classes of chemicals and their biological effects in various species.
By analogy to the GenBank database for genome sequences, researchers will globally query (or
BLAST) CEBS using a transcriptome of a tissue of interest (or a list of outliers) to have the
knowledge base return information on genes, groups of genes, metabolic and toxicological path-
ways, and contextually associated phenotypic information for compounds that display similar
response profiles. With high-quality data content, CEBS will ultimately become a resource to
support hypothesis-driven and discovery research that contributes effectively to drug safety and
the improvement of risk assessments for chemicals in the environment. The CEBS development
effort will span a decade or more. Key words: bioinformatics, compendia, database, global query,
gene expression, heuristic algorithms, knowledge base, linkage-disequilibrium, metabonomics,
microarray, molecular expression, ontologies, phenotype, phenotypic anchoring, proteomics,
sequence, single nucleotide polymorphisms, systems biology, systems toxicology, toxicogenomics,
transcription factors. Environ Health Perspect 111:811–824 (2003). doi:10.1289/txg.5971
available via http://dx.doi.org/ [Online 7 November 2002]
Toxicogenomics Reviewwill incorporate high-quality data sets from
each of the new toxicogenomics technolo-
gies as well as from contemporary molecular
and cellular toxicology. 
The goals of CEBS are a) to create a
reference toxicogenomic information sys-
tem of studies on environmental chemi-
cals/stressors and their effects; b) to
develop relational and descriptive compen-
dia on toxicologically important genes,
groups of genes, single nucleotide poly-
morphisms (SNPs), and mutant and
knockout phenotypes in animal models
relevant to human health and environmen-
tal disease; and c) to support hypothesis-
driven research and discovery research in
environmental toxicology. We must
approach these goals in an incremental
fashion, recognizing that in the face of
rapid technological change it is impossible
to anticipate all opportunities and problems
that can develop. 
The conceptual design framework for
CEBS is based upon functional genomics
approaches that have been used successfully
in analyzing yeast gene expression data
sets (Hughes et al. 2000). The proposed
framework is illustrated in Figure 1.
Because CEBS will contain data on
global gene expression, protein expression,
metabolite profiles, and associated chemi-
cal/stressor-induced effects in multiple
species (e.g., from yeast to humans), it will
be possible to derive functional pathway
and network information based on cross-
species homology. CEBS data sets will be
fully documented in experimental proto-
cols and therefore searchable by com-
pound, structure, toxicity end point,
pathology end point, gene, gene group,
etc., as a function of dose, time, and the
condition of the target tissue. Controlled
vocabularies, dictionaries, and descriptive
explanatory text or metadata (that can be
processed by a computer) will guide
researchers in understanding toxico-
genomics data sets. A knowledge base will
be developed by carefully assimilating
toxicological, biological, and chemical
information from multiple public domain
databases and by progressively reﬁning that
information about classes of chemicals and
their biological effects in various species
(Tennant 2002; Zweiger 1999). By analogy
to the GenBank database for genome
sequences, ultimately it will be possible to
query the CEBS globally using a transcrip-
tome of a tissue of interest (or a list of out-
liers from a gene expression analysis) to
BLAST (Altschul et al. 1990) the knowl-
edge base and have it return information on
genes, groups of genes, metabolic and toxi-
cological pathways, and associated pheno-
typic information observed in data sets for
hits (i.e., compounds that display similar
effects in multiple tissues and species, and
the dose, time, and phenotypic severity
with which these effects are observed). With
the expected high-quality data content,
CEBS will rapidly become an important
scientific resource that provides users with
the suite of tools needed to interpret
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Figure 1. Conceptual framework of the CEBS knowledge base—a cross-species reference toxicogenomic information system on chemicals/stressors and
their effects. NLM, National Library of Medicine.
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As compendia of expression proﬁles are
indexed and compared to discern diagnostic
signatures, it will become increasingly possi-
ble to characterize an unknown physical or
chemical exposure by comparing its gene or
protein expression proﬁle to proﬁles in the
database. Joint research by scientists at the
NIEHS Microarray Center (NMC) and
Boehringer-Ingelheim Pharmaceuticals has
shown that global gene expression profiles
for chemicals from different mode-of-action
classes can provide gene expression “signa-
tures” of chemical exposures in male rats
(Hamadeh et al. 2002b, 2002c). These stud-
ies were performed on acutely exposed ani-
mals, and the expression patterns appear to
be representative of the adaptive or pharma-
cological activity of the chemicals. Using a
small training set, Hamadeh et al. (2002d)
were able to correctly ascertain chemical
class signatures based on pattern recognition
of genes induced acutely. This study, in
essence, validated the toxicogenomics
hypothesis that knowledge can be gained
regarding the nature of blinded samples
using an initial training set of chemicals.
NCT Intramural Research
Current NCT research aims to formally
discriminate between “chemical signatures”
reﬂecting early adaptive or pharmacological
responses with no ensuing pathology and
“effects signatures” that entail altered tissue
steady state, toxicity, histopathology, or
disease (Bartosiewicz et al. 2001). We are
therefore developing learning sets of
genomic proﬁling data for various classes of
agents, with doses ranging from those that
are pharmacologic to those that are toxic.
We will also perform comparative studies
that address cross-species differences in tox-
icological responses as well as susceptibility
differences in human subgroups. 
The combined and integrated data on
gene/protein/metabolite changes collected
in the context of dose, time, target tissue,
and phenotypic severity across species are
providing the interpretive information
needed to define the molecular basis for
chemical toxicity and to model the resulting
toxicological and pathological outcomes
(Boorman et al. 2002). It will then be feasi-
ble to search for evidence of exposure or
injury prior to any clinical or pathological
manifestation, facilitating identification of
early biomarkers of exposure, toxic injury, or
susceptibility. We anticipate that toxicoge-
nomics research will lead to the identifica-
tion, measurement, and evaluation of
biomarkers that are more accurate, quantita-
tive, and speciﬁc. These biomarkers will be
recognized as important factors in a
sequence of key events that will help to
define the way in which specific chemicals
or environmental exposures cause disease. In
other words, toxicogenomics will help to
delineate the mode of action of various
classes of agents and the unique attributes of
certain species and population subgroups
that render them susceptible to toxicants as
an important step in comparatively assessing
potential human health risk (Farland 1992). 
NCT intramural scientists are now
performing additional proof-of-principle
experiments designed to establish how
effects signatures can be deﬁned and to link
the patterns of altered gene expression to
speciﬁc parameters of well-deﬁned, conven-
tional indices of toxicity. For example,
experiments are being designed to correlate
gene expression patterns with liver patholo-
gies such as hepatomegaly, hepatocellular
necrosis, or inﬂammation. It is also possible
to look for correlative patterns, for exam-
ple, in enzyme levels, in liver, and in other
tissues or cells such as blood. Changes in
serum enzymes provide diagnostic markers
of organ function that are commonly used
in medicine and in toxicology. This “phe-
notypic anchoring” of gene expression data
to conventional indices removes some of
the subjectivity of conventional molecular
expression analyses and helps to distinguish
the toxicological signal from other gene
expression changes that may be unrelated
to toxicity, such as the varied pharmacolog-
ical or therapeutic effects of a compound
(Tennant 2002).
Future NCT studies will deﬁne molecu-
lar perturbations caused by environmental
chemicals in terms of phenotypic severity,
dose, and time (Hamadeh 2002b). We will
explore quantitative or absolute gene
expression profiling (Dudley et al. 2002)
and consider combining such an approach
with physiologically based pharmacokinetic
(PB/PK) and pharmacodynamic modeling.
PB/PK modeling can be used to derive a
quantitative estimate of target tissue dose at
any time after treatment, thus creating the
possibility of anchoring molecular expres-
sion profiles in internal dose as well as in
time and phenotypic severity. Relationships
among gene, protein, and metabolite
expression may then be described as a func-
tion of the applied dose of an agent and the
ensuing kinetic and dynamic dose–response
behavior in various tissue compartments. In
addition, the species under study and the
interspecies interindividual differences must
be considered. With the aid of the knowl-
edge systematically generated and assem-
bled (Zweiger 1999) through literature
mining, comparative analysis, and iterative
biological modeling of molecular expression
data sets over time, the adaptive responses of
biological systems will be differentiated from
those changes associated with or precedent
to clinical or visible adverse effects. We
anticipate that our understanding of mecha-
nisms of toxicity and disease will improve as
these new methods are used more exten-
sively and toxicogenomics databases are
developed more fully. The expected result
will be the emergence of toxicology as an
information science that will enable thor-
ough analysis, iterative modeling, and dis-
covery across biological species and chemical
classes. CEBS is being designed to meet the
information and modeling requirements of
an integrated systems toxicology illustrated
conceptually in Figure 2.
A key priority for NCT intramural
toxicogenomics studies is the profiling of
specific compounds and disease processes
that lead to target organ toxicities (e.g.,
hepatotoxicity and nephrotoxicity). These
studies will entertain the following consid-
erations, and emphasis will be on the early
steps in the disease processes. Multiple
compounds that elicit a particular hepato-
toxicity or nephrotoxicity will be studied at
multiple sampling times after exposure.
Subtoxic as well as toxic doses will be used,
and nontoxic isomers and related com-
pounds will be included to assess the speci-
ficity of effects observed. Drugs and
chemicals will be selected for study on the
basis of criteria such as human exposure and
recent toxicology studies demonstrating
consistent cross-species effects. Ideally, a
drug will show a therapeutic effect, and
chemicals will display mechanism(s) of toxi-
city that are prototypical for other agents,
including those in our proof-of-principle
studies. For example, acetaminophen, or
paracetamol, is the ﬁrst agent to be studied
comprehensively by the NCT. Selection
was based on an extensive literature
(Bessems and Vermeulen 2001) showing
that liver toxicity from this agent is a com-
mon response in rodents and in humans; its
metabolism is similar in rodents and in
humans; it displays both therapeutic and
toxic effects; and there are opportunities for
clinical investigation. Furthermore, aceta-
minophen has been studied by several labo-
ratories using toxicogenomic methods
(Cunningham et al. 2000; Reilly et al.
2001a, 2001b; Ruepp et al. 2002; Yamazaki
et al. 2002), which offers the possibility of
comparative assessment of observed molec-
ular expression, toxicology, and pathology.
Toxicogenomics Research
Partnerships
The magnitude and complexity of the
science underlying the broad goals of the
NCT is such that no one organization has
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resources with which to solely accomplish
them. A central strategy of the NCT, there-
fore, is the development of partnerships
with universities, other federal research and
regulatory agencies, and the private sector
through the formation of consortia that
will address critical scientific challenges in
toxicogenomics. The NCT is, in fact, a
synergistic collaboration between intra-
mural and extramural scientists based on
research partnerships. 
Operating under a National Institutes
of Health cooperative agreement mecha-
nism, the Toxicogenomics Research
Consortium (TRC) is a key model for
achieving the strategic objectives of the
NCT. The TRC consists of five academic
centers in addition to the NMC: University
of North Carolina at Chapel Hill; Fred
Hutchinson Cancer Research Center,
Seattle, Washington; Oregon Health and
Science University, Portland, Oregon;
Duke University, Durham, North Carolina;
and Massachusetts Institute of Technology,
Cambridge, Massachusetts. The consortium
members provide specialized expertise in
gene expression proﬁling and bioinformat-
ics; they will perform both independent and
cooperative research on various aspects of
toxicogenomics. In the current state of gene
expression technology, various methodolo-
gies for arraying genes and assessing mRNA
expression, as well as multiple bioinformat-
ics tools, are being applied in the analysis
and management of such data. Therefore,
an initial goal of the TRC is to perform a
series of “standardization” experiments for
gene expression in order to address sources
of variation, develop standard practices, and
establish data quality criteria and bioinfor-
matics standards. Initial proof-of-principle
experiments are being performed to assess
the ability of the consortium members to
perform standardized toxicogenomics
experiments and to exchange and interpret
data across multiple microarray platforms.
Data generated from such experiments will
be incorporated into the CEBS knowledge
base and ultimately will be used to design
further hypothesis-driven research. The
TRC will build on these standardization
experiments in performing additional col-
laborative studies to investigate molecular
responses to various environmental stres-
sors. These efforts of the TRC will make a
unique contribution to the field of toxi-
cogenomics and to the quality of the CEBS
knowledge base.
The NCT participates in a second
consortium that addresses many of the same
platform and bioinformatics issues as the
TRC: the Health and Environmental
Sciences Institute of the International Life
Sciences Institute (ILSI/HESI) (http://hesi.
ilsi.org/activities/index.cfm?pubentityid=8).
ILSI/HESI is coordinating the efforts of
approximately 30 pharmaceutical compa-
nies in a worldwide effort to harmonize
cross-platform gene expression data and
analysis methods. The ILSI Genomics
Project is focusing on three categories of
toxicants: in vivo hepatotoxins, in vivo
nephrotoxins, and in vitro genotoxins. The
NCT is involved in the former two cate-
gories of study in which animals were
dosed, tissues were taken for histopathology
and RNA extraction, and RNA samples
were then distributed to participating labo-
ratories for microarray analysis using meth-
ods chosen by the respective participating
laboratories. This type of collaboration will
minimize problems associated with RNA
extraction and quality control issues and
provide a basis for direct comparisons
among various microarray platforms. 
CEBS will house data from NIEHS
intramural and extramural research pro-
grams and will accept high-quality data sets
from other federal, academic, and indus-
trial partners. For example, through the
courtesy of Abbott Laboratories, Rosetta
Inpharmatics, Rosetta Biosoftware, and
Merck Pharmaceuticals, a set of data from
hepatotoxicity experiments on more than
60 chemicals and drugs (52 hepatotoxins)
is being made available to the NCT
(Waring et al. 2003). By agreement with
these private sector partners, this learning
data set will be made publicly available via
CEBS to the research community. 
Microarray Analysis 
Microarray data resulting from intramural
NCT toxicogenomics experiments are cur-
rently captured in the NIEHS MicroArray
Project System (MAPS). MAPS is a labora-
tory management information system
developed at NIEHS (Bushel et al. 2001) in
which approximately 40 data fields are
defined to a) manage microarray project
information; b) detail experimental design;
c) track clones, sample preparation, labeling
and hybridization; and d) survey the quality
control and assurance of processed microar-
ray chips. The NMC currently produces
Yeast Chip v. 1 (6.2 K clones) and four
mammalian chips: the Human ToxChip v.
3. (2.2 K clones), the Rat ToxChip v. 2.
(6.8 K clones), and human and mouse
oligonucleotide discovery chips (17.0 K and
16.0 K oligonucleotides, respectively). Gene
accession numbers for each gene or
expressed sequence tag (EST) on each chip
are automatically updated biweekly from
http://www.ncbi.nlm.nih.gov/UniGene/
to reflect the current National Center
for Biotechnology Information (NCBI)
814 VOLUME 111 | NUMBER 6 | May 2003 • Environmental Health Perspectives
Toxicogenomics | Waters et al.
Figure 2. Interpretation of molecular expression proﬁles with literature mining, phenotypic anchoring, and
iterative biological modeling for systems toxicology. ADME refers to absorption, distribution, metabolism,
and excretion.
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ADME, metabolitesUniGene build. Hundreds of thousands of
novel EST sequences have been included in
NCBI’s UniGene. NMC cDNA chips
include a substantial proportion of ESTs,
thus offering the potential to discover
novel genes involved in important biologi-
cal or toxicological outcomes and disease
processes. To provide some perspective on
the information management requirements
of gene expression analysis, we have illus-
trated in Figure 3 the image and data analy-
sis processes for microarray experiments.
Implementation of a CEBS
Prototype 
With the assistance of the NIEHS
Computer Technology Branch, the NCT is
currently implementing a prototype ver-
sion of the CEBS database through the
application and integration of software
developed for the NMC and the National
Toxicology Program (NTP). Toxicology
and pathology data from intramural NCT
toxicogenomics experiments are currently
being captured in the NTP’s Toxicology
Database Management System (TDMS) in
an Oracle database and are being integrated
with microarray gene expression data
(Figure 4).
Prototype CEBS (Model A) will be a
temporary workbench for concept deﬁnition
and systems integration in the development
of CEBS. Nevertheless, this model will pro-
vide early public web access to NCT data
sets and will implement software applica-
tions and statistical server routines required
to analyze microarray data and associated
toxicological information. It will provide
MIAME (minimal information about a
microarray experiment) (Brazma et al.
2001), supporting the MIAME standard of
the Microarray Gene Expression Database
(MGED) Society (http://www.mged.org/).
The underlying motivation for MIAME is
to enable the establishment of public reposi-
tories for microarray data and to serve as a
basis for designing a microarray data
exchange format or markup language
Toxicogenomics | The CEBS knowledge base
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Figure 3. Components of the microarray image and data analysis process. Abbreviations: AIMS, Analysis Information Management System; cal., calibrated; LIMS,
Laboratory Information Management System; QA/QC, quality assurance/quality control.
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Many additional database standards are
under review for use in the development of
CEBS, but perhaps the most important
ones are those under the purview of
MGED. MGED has expert working
groups on a) experimental description and
data representation standards; b) microar-
ray data extensible markup language
(XML) exchange format (CEBS will use
XML for data exchange); c) ontology
(Karp 2000) for sample description (CEBS
will follow the gene ontologies of the Gene
Ontology (GO) Consortium at http://
www.geneontology.org/ for biological
process, molecular function, and cellular
component); d) normalization, quality
markup control, and cross-platform com-
parison; and e) future user group queries,
query language, data mining, all of which
will provide important input for the
development of CEBS. In addition,
MGED has developed the microarray
gene expression-object model (MAGE-
OM), which will be used to develop pro-
teomics and toxicology object models for
CEBS. The NIEHS Scientific Computing
Laboratory is currently pursuing require-
ments definition and object modeling for
proteomics and toxicology to facilitate a
seamless future integration of gene, pro-
tein, and toxicology/pathology databases.
It should be noted also that the TRC is
fully operational and is presently receiving
database and bioinformatics support
through Srinivasa Nagalla at the Oregon
Health and Science University (OHSU)
http://medir.ohsu.edu/~geneview/. OHSU
has implemented an Oracle version of
GeneX developed at the National Center
for Genome Resources. The resource con-
tractors who will support the TRC will
come on line early in 2003. They will
begin to receive samples from the TRC
and to provide data sets to the CEBS pro-
totype in 2004. With the simultaneous
development of the NCT proteomics
resource contract, the metabonomics
research effort, and further expansion of
NCT programs, data, and information
resources, the CEBS prototype will begin
to evolve into the CEBS knowledge base.
Systems Toxicology—
Bioinformatics and
Interpretive Challenges
To develop a toxicogenomics knowledge
base that will support the requirements of
systems toxicology, we must address bioin-
formatics and interpretive challenges at
multiple levels of biological organization
and phenotypic severity. Figure 5 illustrates
some of these challenges as molecular
expression analysis is used to monitor the
sequential adaptive, pharmacological, toxi-
cological, and pathological events observ-
able in biological systems after exposure to
a chemical. 
The lower levels of complexity (genes,
gene groups, functional pathways) reflect
our current levels of understanding and our
ability to describe and package that knowl-
edge using what might be termed “linear
bioinformatics.” In fact, risk assessors seek
to deﬁne a sequence of key events and com-
mon (linear) modes of action for environ-
mental chemicals and drugs (Farland 1992,
1996; Larsen et al. 2000). The networks
and systems level of biological organization
reflects global bioinformatics challenges,
wherein the cell expresses global change
constantly in response to environmental
stimuli. This is a systems biology reality
that can only be addressed using fully con-
text-documented toxicogenomics data sets
properly assembled with appropriate statis-
tical and mathematical modeling to develop
an integrated systems toxicology. However,
a substantial amount of data entry, data pro-
cessing, and knowledge building must be
performed before such advanced bioinfor-
matics approaches can be applied. It should
be recognized that the development of a
knowledge base to accurately reﬂect global
molecular expression and to aid systems bio-
logical interpretation is a complex issue dealt
with only superﬁcially in the present discus-
sion. Keeping these challenges and concepts
in mind, we now present some conceptual
arguments regarding the phased develop-
ment of the CEBS knowledge base—a
process that undoubtedly will require a
decade or more to complete. Progress in the
development of CEBS can be monitored at
http://www.niehs.nih.gov/nct/.
Phased Development of the
CEBS Knowledge Base
The CEBS knowledge base will be devel-
oped in four substantially overlapping
phases: Phase I involves the gathering of
microarray gene expression, toxicology and
pathology data, and development of gene
and protein annotation and bioinformatics
tools. Phase II incorporates corresponding
proteomics data sets with similar annota-
tion and bioinformatics tools and develops
a temporary proteomics database. Phase III
integrates gene, protein, and (ideally)
metabolite databases and links them with
numerous internet resources for metabolic
and functional pathway discovery. Phase IV
adds two additional databases, one on gene
and protein groups and one on SNPs to
what has been described above. The three
databases then are integrated with a series of
bioinformatics tools (data and literature
mining) and computational algorithms
designed to generate new knowledge. 
CEBS Phase I: Microarray Gene
Expression Data, Toxicology/
Pathology Data, and Associated
Analysis Tools
CEBS Phase I will be a public toxico-
genomics database containing data sets
from the TRC, the intramural NCT
research program, and from industrial and
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Figure 5. Interpretive bioinformatics challenges at
levels of increasing biological complexity in a
paradigm leading from chemical exposure to
adverse outcomes.
Chemical exposure
(structure–activity relationships)
Gene/protein groups
(functional characterization)
Multiple genes/proteins
(annotation)
Pathways
(sequential events)
Networks and systems
(integrated responses)
Toxicology/pathology
(adverse effects)
Figure 6. Microarray experimental components—information management (IM) systems for data acquisi-
tion and biological interpretation.
Tasks, content, and IM systems
CEBS Track Systems
Chip design Which genes/probes/clones? LIMS
Chip construction Chip layout, printing AIMS
Data acquisition RNA extraction, labeling, hyb, image capture LIMS
Image analysis Convert scanned image to expression levels AIMS
Data analysis Normalization filtering, clustering, classification, Software
pattern discovery, biological interpretationgovernmental partners. It will comprise
mainly microarray and toxicology data and
information. To assist the TRC in populat-
ing CEBS with microarray data, the NCT
awarded a resource contract to provide
access to high-throughput microarray gene
expression analysis. As illustrated in Figure
6, CEBS Phase I will track all microarray
technical and experimental components
relating to chip design, construction, data
acquisition, image analysis, and data
analysis. It will also track clone set gene
sequences, descriptors and other genomic
annotations, and associated toxicological/
pathological end points, and will provide
basic bioinformatics tools for data analysis
and biological interpretation. 
CEBS Phase I will be protocol driven.
All data sets within CEBS will be linked by
reference to an experimental protocol num-
ber and metadata that will specify standard
operating procedures, observations, and
measurements to be recorded. CEBS
Phase I will include complete sample anno-
tation (e.g., sample name, organism,
biosource provider, sample source, devel-
opmental stage, age and units, time points,
organ/tissue, growth conditions, medium,
culture temperature, genetic variation,
individual name or ID, disease state, addi-
tional clinical information and units, target
cell type, cell line, treatment application,
treatment type, separation technique, sam-
ple extraction method, amplification
method, label, etc. All the data types (num-
bers, graphs, observations, images, etc.) will
be related by the experimental protocol.
The data to be stored and their location
will be similarly identiﬁed in the process of
defining the experimental protocol, as will
reports to be generated and analyses to be
performed. The purpose of this high degree
of context documentation is to facilitate
extensive query and biological interpreta-
tion. Domain-specific metadata will intro-
duce experimental data sets in each
analytical domain: transcriptomics, toxicol-
ogy, pathology, etc. CEBS Phase I will
incorporate raw microarray image files as
well as fully processed outlier gene lists
together with appropriate visualization
tools. Results will be displayed or juxta-
posed in various “views,” or graphic user
interfaces, that will provide insights, facili-
tate further analysis, and suggest new
hypotheses to test. 
CEBS also will access biological, chemi-
cal, and toxicological resources in public
domain databases, as well as pathway infor-
mation such as that available in the Kyoto
Encyclopedia of Genes and Genomes
(KEGG) at http://www.genome.ad.jp/kegg/
(Ogata et al. 1999) and What Is There?
(WIT) at http://wit.mcs.anl.gov/WIT2/
(Selkov et al. 1998). Links will be built to
other databases such as the European
Bioinformatics Institute (EBI) ArrayExpress
database (http://www.ebi.ac.uk/microarray/
ArrayExpress/arrayexpress.html), the National
Library of Medicine’s Gene Expression
Omnibus (GEO) Database at http://www.
ncbi.nlm.nih.gov/geo/ (Edgar et al. 2002),
and the NTP’s new Oracle toxicology
information bank. 
To address the ﬁrst of the bioinformatics
and interpretive challenges mentioned
above, basic gene annotation in CEBS Phase
I will be largely automated; annotation
resources will be routinely consulted to pro-
vide a complete range of updated gene/pro-
tein information. The process of gene
annotation is illustrated in Figure 7, and
some major biological data and information
resources for gene annotation are shown in
Table 1. The links for these annotation
resources were operational at the time of
publication of this article. However, please
consult the NCT website for a current list of
links (http://www.niehs.nih.gov/nct/).
Continuous reﬁnement of gene annota-
tion and sequence definition will improve
the interoperability of cross-platform data
sets (Zweiger 1999). Steps for keeping
sequence data current can be as follows:
a) sequence all cDNA clones sets and refer
to the known sequences of oligonucleotide
sets, b) reference GenBank accession num-
bers and UniGene ID numbers for genes,
and GenBank accession numbers and
dbEST cluster ID numbers for ESTs, c) ref-
erence TIGR Gene Indices (http://www.tigr.
org/tdb/tgi.shtml) for EST or oligonucleotide
consensus sequence (Quackenbush et al.
2001) and MegaBLAST against Trace
Archives for genomes of interest. Mega-
BLAST against Trace Archives compares
nucleotide sequence data against the current
raw data underlying ﬁrst-pass sequence gen-
erated by various genome sequencing cen-
ters. This is particularly important for the
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Figure 7. Information (annotation) associated with a single gene. Adapted from Gibas and Jambeck 2001. 
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Table 1. Some major biological data and information resources for gene annotation.a
Subject Source Link
Biomedical literature PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgil
Nucleic acid sequence GenBank http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=nucleotide
(e.g., for the rat)  RGD http://rgd.mcw.edu/ ebEST; http://rgd.mcw.edu/EBEST/
Annotation (mouse) MGI http://www.informatics.jax.org/
Genome sequence GenBank http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=genome
http://www.ncbi.nih.gov/PMGifs/Genomes/euk_g.html
TIGR http://www.tigr.org/tdb/; http://www.tigr.org/tdb/tgi/
Protein sequence GenBank http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=protein
Swiss-Prot http://www.expasy.ch/sprot/
Protein structure Protein DB http://www.rcsb.org/pdb/
PIR http://www-nbrf.georgetown.edu
Protein mass spectra PROWL http://prowl.rockefeller.edu
Posttranslational mods RESID http://www-nbrf.georgetown.edu/pirwww/search/textresid.html
Biochemical pathways KEGG http://www.genome.ad.jp/kegg//
WIT http://wit.mcs.anl.gov/WIT2/; http://emp.mcs.anl.gov
PathDB http://www.ncgr.org/software/pathdb/
aAdapted from Gibas and Jambeck (2001).rat genome, which is presently very incom-
plete. This effort to derive new information
about incomplete genomes will substantially
enhance the discovery value of ESTs on
cDNA chips and will facilitate cross-species
investigation of gene/protein functional
analogies, which we will discuss further. 
Functional characterization presents a
second bioinformatics and interpretive
challenge. Functional characterization can
involve the grouping of similar genes and
gene products. A number of conventional
means can accomplish this, including
supervised and unsupervised classifica-
tion/prediction, artificial intelligence, and
various genetic algorithms as well as a
number of annotation resources just dis-
cussed. We propose to use these methods
and resources in concert with query of the
scientiﬁc literature to develop knowledge of
the function of genes and gene products.
Literature queries can facilitate gene
annotation as well as biological interpreta-
tion of microarray expression results. The
challenge is to deal not only with accepted
microarray gene annotation names but also
with legacy data in the earlier scientific
literature, with the ultimate objective of
making linkages of gene and protein anno-
tations with literature on the basis of
sequence information. MEDLINE, the
most widely accessible repository of the
biomedical literature, currently contains
over 11 million abstracts and is growing
rapidly. Unfortunately, it is difﬁcult to use
the gene name found in a nucleotide
sequence database record (or as presented
on a list of outliers) to search the biomed-
ical literature effectively. 
The generation of names for genes and
gene products based on sequence informa-
tion is a significant challenge. Ultimately,
genes and gene products must be linked by
sequence data. Sequence-based synonym
naming requires expertise in both data
extraction and bioinformatics. Expertise in
bioinformatics is required, as much of the
searching will need to be done using
BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/; Altschul et al. 1990). Genomic
BLAST pages are available for human,
mouse, rat, zebraﬁsh, and other eukaryotic
and microbial genomes at the NCBI’s
BLAST website just mentioned. 
Nucleotide sequence databases, e.g.,
GenBank or UniGene, do not contain a
“gene product” name field. Instead, the
name is imbedded in other information.
For example, the GenBank nucleotide deﬁ-
nition for “estrogen receptor 1” (the
HUGO recognized name for this receptor)
is “Homo sapiens estrogen receptor 1
(ESR1), mRNA.” Extraction of the appro-
priate search terms estrogen receptor 1 and
ESR1 from the GenBank definition is a
trivial task that becomes intractable when a
large number of genes or protein products
are being searched in the literature, or
when the process is being automated, as is
being contemplated in the development of
the CEBS knowledge base.
To improve the interoperability
between microarray gene annotation and
the scientific literature, all genes in the
clone lists are being provided with vetted
name lists. By vetting, we mean that each
gene name is searched in MEDLINE, and
the way in which MEDLINE parses the
name is examined to ensure that it is being
searched in the desired manner. For exam-
ple, searching MEDLINE via Entrez
(http://www.ncbi.nlm.nih.gov/Entrez/) with
the query phrase “estrogen receptor 1” does
not return any abstracts. Closer inspection
of the search results indicates this is because
this phrase does not occur in the MED-
LINE phrase index. The vast literature
(more than 10,000 abstracts) concerning
this receptor is only accessible with the
legacy names of “estrogen receptor” and
“estrogen receptor alpha.”
Once name lists suitable for searching
MEDLINE are available, we have two tools
to help mine the literature data, OmniViz
and PDQ_MED. OmniViz (Battelle
Memorial Laboratory, Columbus, Ohio) is
a global literature search and visualization
software package that can help greatly in
obtaining an overview of relevant biomed-
ical publications. The proximity-of-data
query software, InPharmix’s PDQ_MED
(Sluka 2002), can facilitate rapid access to
relevant abstracts in MEDLINE for multi-
ple genes (as from a list of outliers).
In CEBS Phase I, a database of gene
identifiers, gene sequence, and synonym
names suitable for searching the scientific
literature will be available; such a database is
currently in beta test at NIEHS for human,
mouse, rat, and yeast chips printed at the
NMC. A web interface to the database will
be provided allowing CEBS users to enter a
chip name and a list of gene IDs or
GenBank accession numbers. The output
from the interface will be the list of names
suitable for searching in MEDLINE or for
use with a literature mining tools such as
PDQ_MED or OmniViz. This is an impor-
tant step toward improving the interoper-
ability between microarray gene annotations
and the scientific literature and ultimately
toward building knowledge in CEBS.
CEBS Phase II: Protein Expression
Database and Metabonomics 
Data Sets
The proteomics efforts within the NCT
consist of an intramural research program,
a proteomics resource contract, and extra-
mural and innovative research grant awards
in proteomics. The close association of the
NCT microarray and proteomics research
groups and the NTP provides a unique
opportunity for integrating genomics, pro-
teomics, and toxicology data sets. The pro-
teomics group and mass spectrometry
group perform hypothesis-driven research
on differentially expressed proteins in key
tissues and biological fluids of interest to
toxicogenomics. A primary platform to
separate and identify proteins used by
NCT proteomics research groups is two-
dimensional (2D) gel protein separation
and mass spectrometry (MS), or 2D–MS.
Analysis by 2D–MS creates protein maps
where proteins for a speciﬁc tissue are orga-
nized by isoelectric point (pI) and molecu-
lar weight (MW). To assist the NCT in
populating CEBS with proteomics data,
the NCT has awarded a proteomics
resource contract that will allow access to
high-throughput 2D–MS capabilities on
an industrial scale. Critical target tissue and
serum from toxicology studies is being ana-
lyzed for differential protein expression. As
discussed earlier, a primary goal of NCT
intramural and contract proteomic studies
is biomarker discovery for proteins (includ-
ing serum/plasma proteins) indicative of
chemical exposure and/or to provide mech-
anistic insight into chemical toxicity.
Therefore, concurrent analysis of serum/
plasma is being performed in addition to
speciﬁc target organs for each study. 
In addition to 2D-MS proteomics, a
new platform called surface enhanced laser
desorption ionization (SELDI) is being
developed intramurally to screen serum
from experimental animals and clinical
sources to ﬁnd new biomarkers (Issaq et al.
2002). Serum proteins are selectively
bound to chemically active surfaces on
SELDI biochips and are rapidly scanned
with high mass accuracy. The normalized
serum mass spectra from chemical treat-
ment or disease groups can be compared
for differences in speciﬁc proteins or in key
clusters of protein masses to serve as bio-
markers of chemical exposure or disease
process. Two other important aspects of
NCT proteomics are the extramural pro-
teomics granting activities through the
Division of Extramural Research (DERT)
and Small Business Innovation Research
(SBIR) awards, which will engage promis-
ing academic research projects in proteo-
mics and also harness new innovative
proteomics technologies for toxicology. 
An interim protein expression database
(PED) will support the intramural proteo-
mics group and the extramural proteomics
resource and resource contract. PED will
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and proteomics best practices. PED will
develop in parallel with the prototypic ver-
sion of CEBS, and the analytical integra-
tion of transcriptomics and proteomics
data will be studied. Many of the stan-
dards and practices applied in the interpre-
tation of microarray and gene expression
are also applicable to the interpretation of
protein expression data sets. Thus, we
anticipate that the object models built by
MGED in the microarray gene expression
database arena also will be applicable to
proteomics and metabonomics. As men-
tioned previously, object modeling for
proteomics is currently being pursued.
Proteomics objects that may be linked in a
linear chain by one-to-many relationships
might include the biological sample, raw
2D-stained gel image, enzyme digest, fea-
ture number (protein spot), MW, pI,
matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry (MALDI-
MS), m/z ions for protein ﬁngerprint iden-
tification, sequence tag from tandem MS
analysis, MS search data results, and pro-
tein identification search results. The
derived objects in the database might
include the study parameters, including
experimental, biological, and toxicological
details; processed gel images; annotated
master gel images for each speciﬁc tissue or
biological fluid; differentially expressed
protein list determined from image analy-
sis; feature (protein spot) table of esti-
mated pI; MW; accession numbers; and
protein functional groups.
CEBS Phase III: Integrate
Microarray Gene Expression and
Protein Expression Databases Using
a Gene/Protein Group Strategy
The integration of microarray/gene expres-
sion and protein expression data is a critical
step that will require development of
knowledge of gene/protein functional rela-
tionships, gene/protein groups, and the
development of algorithms that will
increase our knowledge of the functions of
these groups through actual experimenta-
tion. To build knowledge, we are mining
the published literature for genes and
groups of functionally related genes or pro-
tein products relevant to known end points
in toxicology, pathology, cell regulatory
processes, metabolism, and the like. This
literature mining and analysis process is
using vetted gene names, and the output
will be groups of genes/proteins that repre-
sent putative functional groups based on
the literature. We will then develop algo-
rithms to test these putative functional
gene groups derived from the literature
against treatment-related expression pro-
files and against clustered genes (and co-
regulated ESTs) to confirm gene grouping
on the basis of phenotype (Figure 8). 
This literature-based functional classiﬁ-
cation of gene groups and their association
with known toxicant-responsive pathways
will begin to define the relationships
between gene and protein expression and
our conventional understanding of metabo-
lism, toxicology/pathology, modulation and
homeostasis, cell regulation, and cell signal-
ing. It will also offer an opportunity for dis-
covery of yet unidentiﬁed genes (ESTs) that
are co-regulated with known genes.
To the extent possible, we will conﬁrm
gene group membership by sequence analy-
sis and develop statistical procedures and
algorithms (Wolﬁnger et al. 2001) to con-
tinually refine our knowledge of gene/
protein groups and their relationship to
functional pathways. With sequence deﬁni-
tion of genes, proteins, and gene/protein
group members, it will be possible to begin
to BLAST outlier genes and proteins from
new experimental data sets against data sets
already contained in the CEBS database.
This will begin to facilitate and inform the
integration of transcriptomics and pro-
teomics data sets across treatment, dose,
time, tissue type, and phenotypic severity.
We also propose to integrate metabonomics
data sets into CEBS Phase III because of the
pivotal role that metabolism plays in experi-
mental and clinical toxicology as well as in
hazard identification and risk assessment
(Bundy et al. 2002; Holmes et al. 2000,
2001; Nicholson et al. 1999, 2002).
CEBS Phase IV: Knowledge
Technology
The development of a knowledge base for
systems toxicology will require merging
several different knowledge-building strate-
gies. In addition to mining the literature
for chemical-speciﬁc functionally character-
ized gene/protein groups, testing putative
functional gene/protein groups against
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Figure 8. Literature-derived putative functional gene groups validated against actual expression proﬁles of known toxicant-responsive pathways.
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and cellular componenttreatment-related gene and protein expres-
sion proﬁles, and determining the relation-
ships of these gene/protein groups to
functional pathways, we will consult gene
ontology from the GO Consortium,
http://www.geneontology.org/, and attempt
to verify the accuracy of the ontologies in
terms of biological process, molecular func-
tion, and cellular component. This stan-
dard gene ontology reﬂects broad biological
goals accomplished by ordered assemblies
of molecular functions, tasks performed by
individual gene products, and subcellular
structures, locations, and macromolecular
complexes, respectively.
Standardized gene and protein ontologi-
cal relationships are signiﬁcant in that they
can help to define functional relationships
among genes and groups of genes and pro-
teins. Therefore, we will attempt to conﬁrm
the putative functional relationships across
multiple molecular expression data sets in
the evolving knowledge base. Gene/protein
ontology is an important corollary to the
gene/protein group strategy and may prove
to be an effective approach to the integra-
tion of gene and protein expression data
sets, especially if it can effectively be con-
verted to a heuristic process. As a further
adjunct to the knowledge building, a more
complete and heuristic data compendium
strategy will be devised based on statistical
classification and clustering algorithms (to
look for co-regulation) of genes and pro-
teins as a function of dose, time, and target
site (Figure 9). Here the experimental pro-
tocol deﬁnes the doses and the time course
as well as the bioassays and biological
measurements that will be made. The
bioinformatics protocol speciﬁes the various
statistical and clustering algorithms that will
be applied to look for correlated and co-
regulated genes. Ontologies will be used as
described above. Note that an ontology
lists similar elements, whereas a pathway
describes an interaction among diverse ele-
ments. Using literature-derived putative
gene groups (ideally vetted in appropriate
gene ontologies), an iterative and heuristic
gene/protein group phenotype analysis is
expected to yield validated gene/protein
groups that map to known functional path-
ways and, in terms of toxicology, to deﬁne
the sequence of key events and common
modes of action for environmental chemi-
cals and drugs. Compendia of data will be
assembled within each toxicogenomic and
toxicological/pathological domain. 
Thus, CEBS Phase IV will enable query
by compound, structure and class, toxic or
pathologic effects, gene annotation, gene/
protein groups, and functional (e.g., meta-
bolic and toxicological) pathways that lead
to toxicity and disease. To facilitate inte-
gration of compound-specific data sets, all
genes, proteins, and gene/protein groups
will be linked to the gene/protein name
and sequence database that was described
earlier. This will facilitate query using any
of the query categories listed above.
Ultimately, one will globally query (or
BLAST) the CEBS knowledge base using a
transcriptome of a tissue of interest (or a list
of outliers from gene expression, or proteins
from proteomics analysis) and have the
knowledge base return all similar toxico-
genomics data and data sets as well as con-
textually associated phenotypic information
for compounds tested in various species
and tissues represented in the knowledge
base. This will be possible because of the
derivation and maintenance of up-to-date
sequence information on all genes and pro-
teins represented in the knowledge base. In
a sequence-driven knowledge base, a global
query can return comparative genomic
information (discussed below) based on
BLAST cutoff values selected by the user.
For example, a BLAST-log10 (E-value) cut-
off for human-to-human comparisons
might be 250, whereas rat-to-human may
be 150, and yeast-to-human may be as low
as 100 or less, i.e., the cutoff values are sig-
niﬁcantly organism related and may not be
related to the assigned names of genes. The
actual cutoffs used must also consider the
nature of the query sequence; in particular,
3´ tails (poly-A containing) are more difﬁ-
cult to match across species than are full-
length coding sequences.
A Dose/Phenotype Strategy
Another strategy to be carefully considered
in the development of the CEBS knowl-
edge base is one based on the lowest effec-
tive dose required to produce a particular
molecular expression phenotype or pheno-
type severity. We believe that quantitative
structure–activity relationship (QSARs)
can be developed only for discrete toxico-
genomic events and outcomes that can be
anchored in effective dose and a particular
toxicological/pathological response or out-
come. Precise phenotypic anchoring of dis-
crete toxicogenomic events (derivation of
unique gene/protein group signatures) at
their lowest effective dose will be possible
only if the internal dose can be established
or modeled for the particular agent or its
metabolites in the target tissue. This lowest
effective dose/toxicant signature strategy
has been employed successfully in the
development of the U.S. Environmental
Protection Agency/International Agency
for Research on Cancer genetic activity
profile database (Waters et al. 1991).
Graphic profiles and corresponding data
listings of lowest effective/highest ineffec-
tive doses for genotoxic agents in various
cell types and organisms and for various
end points are available in this database
of approximately 700 compounds. To
develop a similar database for toxico-
genomic end points, one annotates and
organizes gene expression data sets as a
function of compound, organism, end
point, dose, and time for select verified
gene groups and co-regulated ESTs. One
then plots, for example, as a histogram,
outlier upregulated and downregulated
genes for any appropriate toxicological or
pathological end point as a function of
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Figure 9. Heuristic gene/protein functional analysis, including ontological and literature orientation to
describe biological process, molecular function, and cellular component. 
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Resulting histogram plots are pheno-
typically anchored in dose and condition of
target tissue and facilitate ready develop-
ment of global QSARs for compounds and
specific end points under consideration.
Such a quantitative end point profiling
approach can readily be combined with
PB/PK and pharmacodynamic modeling.
(In fact, such modeling can be used to
derive an estimate of internal dose in the
target tissue.) One then has the possibility
to develop quantitative descriptions of the
relationships among gene, protein, and
metabolite expression proﬁles as a function
of applied dose of the agent under consid-
eration and to model ensuing kinetic and
dynamic dose–response parameters in vari-
ous tissue compartments. This is an impor-
tant strategy for CEBS, as it will contribute
directly to future advancements in PB/PK
and pharmacodynamic modeling and sup-
port a formal quantitative risk-assessment
process (Simmons and Portier 2002).
Cross-Species Gene/Protein
Comparative Expression Proﬁling
With the availability of full genome
sequences for several model organisms,
there is intensive research toward the pre-
diction, annotation, and mapping of genes
across species. Of particular interest are the
protein-coding genes and the intracellular
signaling networks and their interactions.
Similarities among novel protein sequences
in model organisms have become an
important and extremely useful source for
hypotheses concerning protein function.
Drosophila melanogaster and Caenorhabditis
elegans are attractive animal model systems
for studying human genes because of their
genetic tractability and their phenotypically
well-characterized genes (Chervitz et al.
1998; Culetto and Sattelle 2000; Nelson
1999a; Rubin and Merchant 2000). 
The genome database at the NCBI has
assembled Clusters of Orthologous Groups
(http://www.ncbi.nlm.nih.gov/COG/) for
homologous nucleotide sequences in more
than 40 species, mainly microbial but
including D. melanogaster, C. elegans, and
Saccharomyces cerevisiae. The functional
analysis of homologous genes in diverse
genetic models is particularly relevant for
proteins involved in human diseases to gain
rapid understanding of human disease
mechanisms and to enhance the probability
for development of novel therapies (Rubin
et al. 2000). 
A number of cell functions are regu-
lated by similar gene families across organ-
isms (e.g., genes for the regulation of the
cell cycle, cytoskeleton, cell adhesion, cell
signaling, and apoptosis). This conserva-
tion of essential genes is also observed for
transcription factors and many downstream
signaling processes. It is believed that the
completion of mouse, rat, and zebrafish
genome sequencing efforts will provide
information not only for the characteriza-
tion of novel genes but also for the exis-
tence of homologous genes involved in
every aspect of cell growth and functional
differentiation. Gaining an understanding
of the evolution and function of stress-
response genes from yeasts to humans, for
example, could be extremely valuable.
Thus, we will provide within CEBS links
appropriate genome information resources
and eventually develop a comprehensive
inventory of homologous genes/proteins
across species from yeast to humans that
may be important in toxicology and human
disease. We anticipate that many of these
homologous genes may be expressed simi-
larly in response to environmental expo-
sures that display similar modes of action.
Strategically, these stressor-responsive genes
and gene clusters could be crucial for the
interpretation of cross-genome expression
proﬁles in an integrated health and ecologi-
cal risk assessment. A core set of homolo-
gous genes should include genes involved
in xenobiotic activation/detoxification
mechanisms, perturbations in cell home-
ostasis mechanisms, oxidative damage, cell
injury, death, and regeneration, and genes
controlling critical signaling mediator mol-
ecules for these biological processes. Phase I
and Phase II enzymes metabolize most
environmental xenobiotic chemicals, and
much is known about their chemical sub-
strates, inducers, and inhibitors. Phase I
enzymes, the cytochromes P450 (CYPs),
bioactivate as well as detoxify xenobiotics.
The primary step involved in the activation
process mediated by CYP proteins is oxida-
tion, or bioactivation of xenobiotics to
electrophiles. Phase II enzymes conjugate
some of these oxidized metabolites to
water-soluble excretable substances. We
will begin our compilation of cross-species
gene/protein comparative expression analy-
sis by focusing on xenobiotic metabolic
enzymes, the CYPs. Approximately 2,500
CYP genes have been characterized from
many organisms (http://drnelson.utmem.
edu/CytochromeP450.html), including bac-
teria and mammalian systems (Nebert and
McKinnon 1994; Nelson 1999b; Nelson
et al. 1996) and their substrate, inducer,
and inhibitor specificities must be studied
in relation to alterations in molecular
expression across species and across classes
of xenobiotics. 
We anticipate that as homologous
genes are identiﬁed, as compendia of gene/
protein expression profiles are developed,
and as functional pathways are derived and
studied across species, we will be able to
begin defining the networks and systems
level of biological organization, wherein the
cell expresses global change in response to
environmental stimuli. Again, we believe
that fully context-documented toxico-
genomics data sets and mathematical mod-
eling will enable development of an
integrated systems toxicology and bioinfor-
matics. In summary, CEBS Phase IV will
create the capability to assess the global
toxicogenomic responses of biological sys-
tems to environmental stressors and to rela-
tionally link toxicogenomics data to
conventional effects data. Because CEBS
Phase IV will include data sets on multiple
experimental organisms, cross-species com-
parisons and extrapolations will be possible
at molecular, subcellular, cellular, organ,
and systems levels.
Further Development of the
Phase IV CEBS Knowledge Base 
On the basis of the foregoing discussion and
advances in the ﬁeld, we have attempted to
describe the basic strategies for the develop-
ment of the core of the CEBS knowledge
base as it is conceptualized at the present
time. Two additional CEBS Phase IV
modules are envisioned for the future. One
is a transcription module that may be used
to predict the expression of genes a priori,
and the other is a haplotype linkage-dise-
quilibrium module that may be used to
predict the differential expression of genes
in human haplotypes and to estimate the
relative sensitivity of population subgroups.
The transcription module will build upon
rapidly developing knowledge of transcrip-
tion factors and their pivotal importance in
gene regulation. Because the number of
transcription factors appears limited
(around 2000 for humans), their study to
include sequence definition and binding
sites can be developed into a predictive
science as related to gene and protein
expression (Forde et al. 2002; Schrem et al.
2002; Wingender et al. 2000, 2001). The
haplotype linkage-disequilibrium module,
on the other hand, will take advantage of
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types and associated SNPs that confer
differential responses within human popu-
lation subgroups to various classes of envi-
ronmental toxicants and stressors (Li 2001).
This module will require the addition of a
SNPs database. NIEHS has for some time
been engaged in the development of the
GeneSNPs Database (http://www.genome.
utah.edu/genesnps/). It should be noted that
SNPs represent only approximately 90% of
all DNA sequence variants. The remainder
includes insertions, deletions, inversions,
and duplications (1 base or many bases or
kilobases). Any or all of these can be
important in any gene being studied. We
anticipate that the addition of a SNPs data-
base will enable an understanding of the
relationship between environmental expo-
sures and human disease susceptibility (Li
2001). This module is important, there-
fore, both in a toxicological and in a risk-
assessment context. Field and clinical
research applications of toxicogenomics
methods are anticipated by the NCT. It is
well known that a single nucleotide poly-
morphism—a single base change in the
message of a gene—can cause a protein to
malfunction. Experimentally, it is possible
to construct panels of mutants that enable
discovery of the impacts of malfunctions in
transcription and translation. 
Preliminary data indicate that gene
expression proﬁles will be useful as diagnos-
tic tools for identifying early stages of vari-
ous pathologies, including cancer (Alaiya et
al. 2002; Alizadeh et al. 2001; Golub et al.
1999; Perou et al. 2000). If this approach
enables earlier detection of disease than is
currently possible through other approaches,
it may allow earlier initiation of therapeutic
interventions. Additionally, gene expression
proﬁling may become an important tool for
predicting therapeutic outcome and may be
particularly useful in addressing the signiﬁ-
cant variability that has been observed in
how well patients respond to different types
of drug therapy. Such patterns of variability
have been studied using expression proﬁling
and, in some cases, expression signatures
have been associated with individuals who
are responders or nonresponders for a partic-
ular type of drug therapy. Once this kind of
result is validated, it may be possible to use
expression profiling to optimize the thera-
peutic regimen for individual patients, thus
increasing the chance of a good treatment
outcome. It may also be possible to identify
susceptible subpopulations for purposes of
quantitative risk assessment.
Conclusions
The NCT and other organizations (Castle et
al. 2002; Pennie and Kimber 2002; Waring
et al. 2001) are performing experiments to
validate the concept of gene expression pro-
ﬁles as signatures of toxicant classes, disease
subtypes, or other biological end points.
Initial studies indicate that classes of toxi-
cants and toxic responses can be recognized
as gene expression signatures using microar-
ray technology. Such experiments have
begun to correlate gene expression profiles
with other well-deﬁned parameters, includ-
ing toxicant class, chemical structure, patho-
logical or physiological response, or other
validated indices of toxicity. For example,
experiments have been designed to correlate
gene expression patterns with liver patholo-
gies such as necrosis, apoptosis, ﬁbrosis, or
inﬂammation. It is also possible to look for
correlative patterns in surrogate tissues such
as blood. Changes in serum enzymes pro-
vide diagnostic markers of organ function
that are routinely used in medicine and in
toxicology. Such phenotypic anchoring of
gene expression data using conventional
indices will distinguish the toxicological sig-
nal from other gene expression changes that
may be unrelated to toxicity, such as the
adaptive, pharmacological, or therapeutic
effects of a compound.
By constructing and populating the
CEBS knowledge base, the NCT is assist-
ing the field of environmental health
research to evolve into an information sci-
ence in which experimental gene and pro-
tein expression data sets are compiled and
made readily available to the scientific
community. Analysis of these expression
proﬁles for different chemicals from differ-
ent classes over dose and time can be used
to identify expression profiles consistently
and mechanistically linked to speciﬁc expo-
sures and disease outcomes. Once sufﬁcient
high-quality data have been accumulated
and assimilated, it will be possible to char-
acterize an unknown biological or physical
sample by comparing its gene and/or pro-
tein expression profile to compendia of
expression proﬁles in the database (Hughes
et al. 2000). The NCT will develop the
capacity to use gene expression signatures
to facilitate toxicological characterization of
toxicants and their biological effects. As the
field of toxicogenomics evolves, toxicoge-
nomics databases will begin to support
predictive toxicology and hazard assess-
ment. This will help scientists predict the
toxicological impact of suspected toxicants
and calculate how much of a hazard these
toxicants actually represent to human and
environmental health. 
Infrastructure development is essential
to facilitate the integration of the existing
public toxicology and structure–activity
databases with those under development in
toxicogenomics (Richard and Williams
2002). In this way, conventional toxicology
and structure–activity databases and the
CEBS public knowledge base can realize
their full potential in supporting mechanis-
tic interpretations and risk assessment
(Simmons and Portier 2002) in the future.
Development of the databases must be
concomitant with the evolution of bioin-
formatics and data mining tools and the
individuals trained to apply them. 
The NIEHS is committed to the devel-
opment of the CEBS knowledge base with
which to initiate this evolutionary process.
This article attempts to provide a vision of
what the CEBS knowledge base will offer
and, in general terms, how it will be con-
structed. The magnitude of the effort
required to develop and populate such a
knowledge base requires a collective will
and collaborative efforts. Therefore, we will
pursue the interoperability of CEBS with
other databases elsewhere (e.g., those on
cell signaling, protein–protein interactions,
and biological and metabolic pathways) to
enhance our ability to interpret toxicoge-
nomic data sets. We will seek to develop
additional mechanisms through which
partnerships with scientists in academic,
private sector, and other governmental
organizations can be created, and we wel-
come advice, criticism, and participation in
this enterprise.
As the CEBS knowledge base expands to
include structurally or functionally related
agents and as gene identity and annotation
progresses, it will be possible to search in a
comprehensive way for common, critical, or
causal relationships. It will then be possible
to create pathway maps of common cellular
processes, to map partial genome arrays to
pathways, and to link such changes to
known phenotypic markers of toxicity. The
proposed knowledge base and its relational
linkages must grow incrementally, and the
developers and users must have the
patience and dedication to stay the course.
Such incremental growth will eventually
become exponential growth and the ﬁeld of
toxicology will be profoundly changed. 
In the realm of molecular epidemiol-
ogy, our growing understanding of
genomic anatomy (gene sequence and
polymorphisms) will form the basis for
characterizing person-to-person and ethno-
geographic sequence variations in genes
that affect responses to drugs and chemicals
that affect human susceptibility/vulnerabil-
ity. Eventually, gene and protein expression
profiles from exposed humans (and from
organisms in the environment) will be
compared with reference expression proﬁles
based on national or international gene
expression databases (Ermolaeva et al.
1998). Studying and analyzing patterns of
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understand the relationship between DNA
sequence variation and the phenotype,
which in turn will help us understand and
integrate the assessment of human and
ecological risk.
Given the vast numbers and diversity of
drugs, chemicals, and environmental
agents, the diversity of species in which they
act, the time and dose factors critical to the
induction of beneﬁcial and adverse effects,
the diversity of phenotypic consequences of
exposures, etc., it is only through the devel-
opment of a profound knowledge base that
toxicology and environmental health can
rapidly advance. Toxicogenomics has the
potential to change how environmental
toxicology is performed. It will contribute
new methods, new data, and new interpre-
tation to the ﬁeld. The ultimate goal of the
NCT is to create a knowledge base that
allows environmental health scientists and
practitioners to understand and prevent
adverse environmental exposures in the
21st century.
Where is the wisdom we have lost in knowl-
edge? Where is the knowledge we have lost in
information?”—T. S. Elliott
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